Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cassava Sciences ( (SAVA) ) has shared an update.
Cassava Sciences held its 2025 Annual Meeting on May 23, 2025, where stockholders voted on five key proposals. Notably, two directors were elected, an amendment to the Non-employee Director Compensation Program was approved, and Ernst & Young LLP was ratified as the independent auditor. However, a proposal to amend the company’s Certificate of Incorporation to reduce board classification was not approved.
The most recent analyst rating on (SAVA) stock is a Buy with a $116.00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page.
Spark’s Take on SAVA Stock
According to Spark, TipRanks’ AI Analyst, SAVA is a Neutral.
Cassava Sciences faces significant financial challenges with no revenue and ongoing operational losses, reflected in the low financial performance score. Technical indicators show bearish trends, and the negative P/E ratio emphasizes valuation concerns. However, the strategic license agreement with Yale University could offer future growth potential, though it currently holds minimal weight due to its speculative nature.
To see Spark’s full report on SAVA stock, click here.
More about Cassava Sciences
Average Trading Volume: 1,595,128
Technical Sentiment Signal: Sell
Current Market Cap: $101.9M
For a thorough assessment of SAVA stock, go to TipRanks’ Stock Analysis page.